1RV Stock Overview
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rhythm Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.00 |
| 52 Week High | US$62.50 |
| 52 Week Low | US$28.60 |
| Beta | 2.09 |
| 11 Month Change | 25.00% |
| 3 Month Change | 43.22% |
| 1 Year Change | 81.53% |
| 33 Year Change | 582.63% |
| 5 Year Change | 179.41% |
| Change since IPO | 162.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1RV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | 0.8% | -1.3% |
| 1Y | 81.5% | -17.5% | 7.4% |
Return vs Industry: 1RV exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 1RV exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 1RV volatility | |
|---|---|
| 1RV Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1RV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1RV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 226 | David Meeker | rhythmtx.com |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
Rhythm Pharmaceuticals, Inc. Fundamentals Summary
| 1RV fundamental statistics | |
|---|---|
| Market cap | €3.48b |
| Earnings (TTM) | -€251.19m |
| Revenue (TTM) | €108.06m |
32.7x
P/S Ratio-14.1x
P/E RatioIs 1RV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1RV income statement (TTM) | |
|---|---|
| Revenue | US$112.53m |
| Cost of Revenue | US$12.81m |
| Gross Profit | US$99.72m |
| Other Expenses | US$361.29m |
| Earnings | -US$261.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.26 |
| Gross Margin | 88.61% |
| Net Profit Margin | -232.45% |
| Debt/Equity Ratio | 71.5% |
How did 1RV perform over the long term?
See historical performance and comparison